There is one clinical trial.
Most patients in intensive care units (ICUs) experience severe sleep disruption. Sleep disruption and sleep alteration may have an influence on the ability to breathe spontaneously. But, the cause of altered sleep remains unknown. Previous studies have shown that decreasing nocturnal respiratory muscle activity through mechanical ventilation might improve sleep quality. Nocturnal respiratory muscle activity may be one of the potential factor which contribute to alter sleep in the ICU. Therefore, the aim of this study is to analyse the presence of NIM activation during the night and it's consequence in an ICU population with the same pathology (COVID 19 ARDS).
Description: Comparison between patients with NIM activation during the night and patients without NIM activation during the night, in patients COVID 19 ARDS with altered spleep. A Polysomnography (PSG) will be performed the night before extubation.Measure: Proportion of patients with altered spleep Time: At day 10 after inclusion
Description: Thanks to a PSG the night befor discharge, the seep architecture will be estimated.Measure: Sleep architecture at hospital discharge Time: At day 28 after inclusion
Description: Thanks to actimetry measure during hospitalization in the post ICU ward.Measure: Sleep monitoring during hospital stay after ICU discharge Time: At day 18 after ICU discharge
Description: Sleep quality will be evaluate by the Pittsburgh sleep quality index. The 7 components of the score add up for give an overall score ranging from 0 to 21 points, 0 meaning that there is no difficulty, and 21 indicating on the contrary major difficulties.Measure: Sleep quality Time: 3 months after hospiotal discharge
Description: Thanks to a PSG at 3 months, the seep architecture will be estimated.Measure: Sleep architecture at month-3 Time: 3 months after hospital discharge
Description: all cost will be estimated during ICU hospitalization.Measure: Cost of ICU hospitalization Time: From inclusion to ICU discharge, up to 10 days after inclusion
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports